PMID- 26425146
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20151001
LR  - 20200930
IS  - 1759-720X (Print)
IS  - 1759-7218 (Electronic)
IS  - 1759-720X (Linking)
VI  - 7
IP  - 5
DP  - 2015 Oct
TI  - Making the next steps in psoriatic arthritis management: current status and 
      future directions.
PG  - 173-86
LID - 10.1177/1759720X15595966 [doi]
AB  - Psoriatic arthritis (PsA) is a chronic inflammatory condition with articular and 
      extra-articular manifestations: peripheral arthritis, axial disease, enthesitis, 
      dactylitis, and skin and nail disease. It is associated with cardiovascular 
      comorbidities. It is now recognized as a new entity, different from rheumatoid 
      arthritis and other spondyloarthritis in terms of clinical manifestations, 
      pathogenesis, and response to therapies. Anti-tumor necrosis factors (anti-TNFs) 
      have demonstrated clinical efficacies exceeding that of conventional disease 
      modifying antirheumatic drugs (DMARDs). The current treatment paradigms recommend 
      early diagnosis and treatment, and a strategic and target orientated approach, 
      aiming at a low disease activity status. New understanding in the 
      immunopathogenesis of PsA has led to new treatment targets. This review addresses 
      the evidence of current treatment for each of the domains as an aid to the 
      clinician managing these patients in the clinic. Some new therapeutic targets are 
      presented. We highlight the importance of development and validation in outcome 
      measures, including that of composite scores that capture various disease domains 
      that will facilitate future clinical trials to inform the best treatment.
FAU - Sritheran, Diviya
AU  - Sritheran D
AD  - Department of Rheumatology and Immunology, Singapore General Hospital, Singapore.
FAU - Leung, Ying Ying
AU  - Leung YY
AD  - Department of Rheumatology and Immunology, Singapore General Hospital, he 
      Academia, Level 4, 20 College Road, 169856, Singapore and Duke-NUS Graduate 
      Medical School, Singapore.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Ther Adv Musculoskelet Dis
JT  - Therapeutic advances in musculoskeletal disease
JID - 101517322
PMC - PMC4572364
OTO - NOTNLM
OT  - disease modifying antirheumatic drug
OT  - psoriatic arthritis
OT  - treatment
OT  - tumor necrosis factor inhibitors
COIS- Conflict of interest statement: The authors declare no conflicts of interest in 
      preparing this article.
EDAT- 2015/10/02 06:00
MHDA- 2015/10/02 06:01
PMCR- 2015/10/01
CRDT- 2015/10/02 06:00
PHST- 2015/10/02 06:00 [entrez]
PHST- 2015/10/02 06:00 [pubmed]
PHST- 2015/10/02 06:01 [medline]
PHST- 2015/10/01 00:00 [pmc-release]
AID - 10.1177_1759720X15595966 [pii]
AID - 10.1177/1759720X15595966 [doi]
PST - ppublish
SO  - Ther Adv Musculoskelet Dis. 2015 Oct;7(5):173-86. doi: 10.1177/1759720X15595966.